[
  {
    "ts": null,
    "headline": "What Investors Should Expect In February 2026's Jobs Report",
    "summary": "What Investors Should Expect In February 2026's Jobs Report",
    "url": "https://finnhub.io/api/news?id=8230ff78a72e03dbb669f61c2101737f4f9870c21fd6c2b4f57f36822764c2dd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772204175,
      "headline": "What Investors Should Expect In February 2026's Jobs Report",
      "id": 139255591,
      "image": "",
      "related": "ELV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=8230ff78a72e03dbb669f61c2101737f4f9870c21fd6c2b4f57f36822764c2dd"
    }
  },
  {
    "ts": null,
    "headline": "Elevance shuffles C-suite as top Carelon exec departs",
    "summary": "The leadership changes at Elevance’s main growth engine Carelon — and the company’s decision to centralize oversight of its health plans — come as Elevance looks to bolster waning profits.",
    "url": "https://finnhub.io/api/news?id=4161e1bd00be27a7316ceceb074a62ad06cbf96ffeef00b8785bd770965e0b88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772189138,
      "headline": "Elevance shuffles C-suite as top Carelon exec departs",
      "id": 139250135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "The leadership changes at Elevance’s main growth engine Carelon — and the company’s decision to centralize oversight of its health plans — come as Elevance looks to bolster waning profits.",
      "url": "https://finnhub.io/api/news?id=4161e1bd00be27a7316ceceb074a62ad06cbf96ffeef00b8785bd770965e0b88"
    }
  },
  {
    "ts": null,
    "headline": "Evaluating Elevance Health (ELV) After Prolonged Share Price Weakness And 17.3% Undervaluation Estimate",
    "summary": "With no single headline event driving attention, Elevance Health (ELV) has drawn investor interest after a mixed share price record, including a 16.18% decline over the past year and a 27.89% decline over three years. See our latest analysis for Elevance Health. Recent trading has been soft, with a 7 day share price return of 7.22% and a year to date share price return decline of 8.81%, while the 1 year total shareholder return decline of 16.18% and 3 year total shareholder return decline of...",
    "url": "https://finnhub.io/api/news?id=a8fcbd4fb5fb542c6f086650ebddff9b8c50193b62befdc8dd2bac48a98bd808",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772162249,
      "headline": "Evaluating Elevance Health (ELV) After Prolonged Share Price Weakness And 17.3% Undervaluation Estimate",
      "id": 139242898,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ELV",
      "source": "Yahoo",
      "summary": "With no single headline event driving attention, Elevance Health (ELV) has drawn investor interest after a mixed share price record, including a 16.18% decline over the past year and a 27.89% decline over three years. See our latest analysis for Elevance Health. Recent trading has been soft, with a 7 day share price return of 7.22% and a year to date share price return decline of 8.81%, while the 1 year total shareholder return decline of 16.18% and 3 year total shareholder return decline of...",
      "url": "https://finnhub.io/api/news?id=a8fcbd4fb5fb542c6f086650ebddff9b8c50193b62befdc8dd2bac48a98bd808"
    }
  }
]